What injectable weight loss medications are recommended for a patient lacking insurance coverage, currently taking Lexapro (escitalopram) and Buspar (buspirone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

I strongly recommend considering oral weight loss medications like phentermine or bupropion/naltrexone (Contrave) since injectable options aren't covered by your insurance. Phentermine (typically 15-37.5mg daily, taken in the morning) is an appetite suppressant that can be effective for short-term use (usually up to 12 weeks) 1. Bupropion (150-300mg daily) might be particularly suitable as it has fewer interactions with your current medications, Lexapro and Buspar. Naltrexone-bupropion combines bupropion with naltrexone and can be taken as directed, usually titrated up to two tablets twice daily.

Key Considerations

  • Before starting any of these, consult with your healthcare provider as they may need to monitor for potential interactions with Lexapro and Buspar.
  • These medications work by either suppressing appetite or affecting brain chemistry related to hunger and cravings.
  • Additionally, incorporate lifestyle modifications like calorie reduction and increased physical activity to maximize effectiveness.
  • Be aware that some side effects may include insomnia, dry mouth, constipation, or increased blood pressure, so regular monitoring is important.

Medication Options

  • Phentermine: 15-37.5mg daily, taken in the morning
  • Bupropion/naltrexone (Contrave): titrated up to two tablets twice daily

Important Notes

  • The choice of agent will depend on the side effects profile of each drug and the patient's tolerance of those side effects 1.
  • There are no data to determine whether one drug is more efficacious than another, and there is no evidence for increased weight loss with combination therapy 1.

From the Research

Weight Loss Medications

Given the lack of insurance coverage for injectable weight loss medications and the patient's current medications, lexapro and buspar, the following weight loss medications can be considered:

  • Orlistat: approved by the FDA for chronic weight management, with a placebo-subtracted weight reduction of 2.9% 2
  • Phentermine/topiramate: approved by the FDA for chronic weight management, with a placebo-subtracted weight reduction of 6.8% 2, and has been shown to have beneficial effects on cardiometabolic risk 3, 4
  • Naltrexone/bupropion: approved by the FDA for chronic weight management, with a placebo-subtracted weight reduction of 4.0% 2
  • Liraglutide: approved by the FDA for chronic weight management, with a placebo-subtracted weight reduction of 5.4% 2

Considerations

When selecting a weight loss medication, it is essential to consider the patient's chronic conditions, comorbidities, and preferences 2. Additionally, the potential risks and benefits of each medication should be weighed, including the increased risk of cancer associated with lorcaserin, which has been withdrawn from the market 2, and the increased heart rate associated with phentermine-topiramate ER 4.

Medication Interactions

There is limited information available on the interactions between these weight loss medications and lexapro and buspar. However, it is crucial to monitor the patient's response to the medication and adjust the treatment plan as needed.

Dosage and Administration

The dosage and administration of these medications can vary, and it is essential to follow the recommended guidelines. For example, phentermine/topiramate ER can be administered in the morning or afternoon, with a dose of 15 mg/92 mg resulting in an average weight loss of 10% of initial weight 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate.

Diabetes, metabolic syndrome and obesity : targets and therapy, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.